<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01988779</url>
  </required_header>
  <id_info>
    <org_study_id>45566</org_study_id>
    <nct_id>NCT01988779</nct_id>
  </id_info>
  <brief_title>Oral Versus Topical Antibiotics for Chronic Rhinosinusitis Exacerbations</brief_title>
  <official_title>Oral Versus Topical Antibiotic Therapy for Treatment of Chronic Rhinosinusitis Exacerbations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Rochester</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to treat patients with a diagnosis of chronic rhinosinusitis
      (CRS) and a history of bilateral endoscopic sinus surgery during times of worsening symptoms
      and signs of acute infection on nasal endoscopy with one of two treatments: (1) oral
      antibiotics and twice daily intranasal saline irrigations or (2) oral placebo and twice daily
      intranasal antibiotic irrigations. The two treatments will be compared to see if there is any
      difference in patient outcomes. This will help guide treatment strategies for patients with
      CRS in the future.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      See brief summary.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 2013</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Actual">September 11, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Rhinosinusitis Disability Index (RSDI) Scores</measure>
    <time_frame>14 days after treatment</time_frame>
    <description>The Rhinosinusitis Disability Index is a 30-item questionnaire completed by the patient or subject. Each item has a value of zero to four, a higher score indicates a self-perception of worse symptoms. The minimum score is zero and the maximum score is 120.
The difference score here is the post-treatment score minus the pre-treatment score, with lower meaning more improvement</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Sino-nasal Outcome Test (SNOT-22) Score</measure>
    <time_frame>14 days after treatment</time_frame>
    <description>The Sino-nasal outcome test is a 22-item questionnaire completed by the patient or subject. Each item has a value of zero to five, a higher score indicates a self-perception of worse symptoms. The minimum score is zero and the maximum score is 110.
The difference score here is the post-treatment score minus the pre-treatment score, with lower meaning more improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Bilateral Endoscopy Findings Using POSE Scores</measure>
    <time_frame>14 days after treatment</time_frame>
    <description>The Perioperative Sinus Endoscopy (POSE) instrument is a specific tool to endoscopically assess the sinus cavities of patients who have undergone endoscopic sinus surgery.
Each POSE score has a minimum of 0 and a maximum of 16, with a higher score indicating a worse outcome.
Here, the Left and Right POSE scores are summed and the difference between baseline and the 14 day after treatment is reported.
The change in bilateral POSE score can in principle be -32 to +32, with increased scores indicating worse outcome and negative scores indicating improvement over the treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-treatment Culture Negativity</measure>
    <time_frame>14 days after treatment</time_frame>
    <description>Post-treatment culture negativity, defined as less than 1+ growth of organisms. A subject is counted '1' if both nares are free of bacterial growth, and '0' if growth is 1+ of more</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Total Bacterial Community Following Treatment as Determined by DNA Sequencing.</measure>
    <time_frame>14 days after treatment</time_frame>
    <description>The bacterial community was determined using a 16S rRNA quantitative PCR processed using Quantitative Insights into Microbial Ecology (QIIME) software, version 1.8 to yield the operational taxonomic units in each subject sample. The scale is bounded at zero with an increasing score indicating a larger number of distinct bacterial species.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Chronic Rhinosinusitis</condition>
  <arm_group>
    <arm_group_label>oral placebo with nebulized intranasal levofloxacin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo oral tablet by mouth daily for 14 consecutive days along with nebulized levofloxacin 125 mg twice daily for 14 consecutive days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>oral antibiotics with nebulized intranasal placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Levofloxacin 500 mg by mouth once daily for 14 consecutive days, along with intranasal placebo solution twice daily for 14 consecutive days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oral levofloxacin</intervention_name>
    <arm_group_label>oral antibiotics with nebulized intranasal placebo</arm_group_label>
    <arm_group_label>oral placebo with nebulized intranasal levofloxacin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nebulized levofloxacin</intervention_name>
    <arm_group_label>oral antibiotics with nebulized intranasal placebo</arm_group_label>
    <arm_group_label>oral placebo with nebulized intranasal levofloxacin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adults (age â‰¥ 18).

          2. Diagnosis of CRS.

          3. Worsening sinonasal symptoms.

          4. Previous bilateral endoscopic sinus surgery (ESS) (including maxillary antrostomy and
             anterior ethmoidectomy).

          5. English speaking.

          6. Open sinuses (open middle meatus bilaterally; determined on endoscopy).

          7. Positive sinonasal culture (1+ or greater) with sensitivity to one of the pre-chosen
             antibiotic regimens.

        Exclusion Criteria:

          1. Patients &lt; 18 years of age.

          2. Treatment with systemic or topical antibiotics within the last 1 month.

          3. Pregnant women.

          4. Non-English speaking persons.

          5. Systemically ill at initial visit necessitating treatment prior to culture data.

          6. Allergies to chosen susceptible antibiotics.

          7. Sinonasal culture with less than 1+ growth.

          8. Multiple organisms grown on culture that are not sensitive to a single antibiotic.

          9. Patients with ciliary function disorders (cystic fibrosis, Kartagener's syndrome,
             ciliary dyskinesia).

         10. Patients with immunodeficiencies.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Li-Xing Man, MD, MPA, Msc</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rochester</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Rochester Department of Otolaryngology Head and Neck Surgery</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>November 13, 2013</study_first_submitted>
  <study_first_submitted_qc>November 13, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2013</study_first_posted>
  <results_first_submitted>November 21, 2019</results_first_submitted>
  <results_first_submitted_qc>November 21, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">December 11, 2019</results_first_posted>
  <last_update_submitted>February 28, 2020</last_update_submitted>
  <last_update_submitted_qc>February 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Rochester</investigator_affiliation>
    <investigator_full_name>Li-Xing Man</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sinusitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levofloxacin</mesh_term>
    <mesh_term>Ofloxacin</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 7, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/79/NCT01988779/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>8 participants screen failed before randomization to the intervention.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Oral Placebo With Nebulized Intranasal Levofloxacin</title>
          <description>Placebo oral tablet by mouth daily for 14 consecutive days along with nebulized levofloxacin 125 mg twice daily for 14 consecutive days
oral levofloxacin
nebulized levofloxacin</description>
        </group>
        <group group_id="P2">
          <title>Oral Antibiotics With Nebulized Intranasal Placebo</title>
          <description>Levofloxacin 500 mg by mouth once daily for 14 consecutive days, along with intranasal placebo solution twice daily for 14 consecutive days.
oral levofloxacin
nebulized levofloxacin</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Oral Placebo With Nebulized Intranasal Levofloxacin</title>
          <description>Placebo oral tablet by mouth daily for 14 consecutive days along with nebulized levofloxacin 125 mg twice daily for 14 consecutive days
oral levofloxacin
nebulized levofloxacin</description>
        </group>
        <group group_id="B2">
          <title>Oral Antibiotics With Nebulized Intranasal Placebo</title>
          <description>Levofloxacin 500 mg by mouth once daily for 14 consecutive days, along with intranasal placebo solution twice daily for 14 consecutive days.
oral levofloxacin
nebulized levofloxacin</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="25"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Rhinosinusitis Disability Index (RSDI) Scores</title>
        <description>The Rhinosinusitis Disability Index is a 30-item questionnaire completed by the patient or subject. Each item has a value of zero to four, a higher score indicates a self-perception of worse symptoms. The minimum score is zero and the maximum score is 120.
The difference score here is the post-treatment score minus the pre-treatment score, with lower meaning more improvement</description>
        <time_frame>14 days after treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral Placebo With Nebulized Intranasal Levofloxacin</title>
            <description>Placebo oral tablet by mouth daily for 14 consecutive days along with nebulized levofloxacin 125 mg twice daily for 14 consecutive days
oral levofloxacin
nebulized levofloxacin</description>
          </group>
          <group group_id="O2">
            <title>Oral Antibiotics With Nebulized Intranasal Placebo</title>
            <description>Levofloxacin 500 mg by mouth once daily for 14 consecutive days, along with intranasal placebo solution twice daily for 14 consecutive days.
oral levofloxacin
nebulized levofloxacin</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Rhinosinusitis Disability Index (RSDI) Scores</title>
          <description>The Rhinosinusitis Disability Index is a 30-item questionnaire completed by the patient or subject. Each item has a value of zero to four, a higher score indicates a self-perception of worse symptoms. The minimum score is zero and the maximum score is 120.
The difference score here is the post-treatment score minus the pre-treatment score, with lower meaning more improvement</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.000" spread="29.47"/>
                    <measurement group_id="O2" value="-14.82" spread="13.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Assuming that the non-inferiority limit of topical therapy is 20% of that for oral therapy.</non_inferiority_desc>
            <p_value>0.505</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Sino-nasal Outcome Test (SNOT-22) Score</title>
        <description>The Sino-nasal outcome test is a 22-item questionnaire completed by the patient or subject. Each item has a value of zero to five, a higher score indicates a self-perception of worse symptoms. The minimum score is zero and the maximum score is 110.
The difference score here is the post-treatment score minus the pre-treatment score, with lower meaning more improvement</description>
        <time_frame>14 days after treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral Placebo With Nebulized Intranasal Levofloxacin</title>
            <description>Placebo oral tablet by mouth daily for 14 consecutive days along with nebulized levofloxacin 125 mg twice daily for 14 consecutive days
oral levofloxacin
nebulized levofloxacin</description>
          </group>
          <group group_id="O2">
            <title>Oral Antibiotics With Nebulized Intranasal Placebo</title>
            <description>Levofloxacin 500 mg by mouth once daily for 14 consecutive days, along with intranasal placebo solution twice daily for 14 consecutive days.
oral levofloxacin
nebulized levofloxacin</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Sino-nasal Outcome Test (SNOT-22) Score</title>
          <description>The Sino-nasal outcome test is a 22-item questionnaire completed by the patient or subject. Each item has a value of zero to five, a higher score indicates a self-perception of worse symptoms. The minimum score is zero and the maximum score is 110.
The difference score here is the post-treatment score minus the pre-treatment score, with lower meaning more improvement</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.333" spread="33.02"/>
                    <measurement group_id="O2" value="-18.73" spread="12.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Bilateral Endoscopy Findings Using POSE Scores</title>
        <description>The Perioperative Sinus Endoscopy (POSE) instrument is a specific tool to endoscopically assess the sinus cavities of patients who have undergone endoscopic sinus surgery.
Each POSE score has a minimum of 0 and a maximum of 16, with a higher score indicating a worse outcome.
Here, the Left and Right POSE scores are summed and the difference between baseline and the 14 day after treatment is reported.
The change in bilateral POSE score can in principle be -32 to +32, with increased scores indicating worse outcome and negative scores indicating improvement over the treatment period.</description>
        <time_frame>14 days after treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral Placebo With Nebulized Intranasal Levofloxacin</title>
            <description>Placebo oral tablet by mouth daily for 14 consecutive days along with nebulized levofloxacin 125 mg twice daily for 14 consecutive days
oral levofloxacin
nebulized levofloxacin</description>
          </group>
          <group group_id="O2">
            <title>Oral Antibiotics With Nebulized Intranasal Placebo</title>
            <description>Levofloxacin 500 mg by mouth once daily for 14 consecutive days, along with intranasal placebo solution twice daily for 14 consecutive days.
oral levofloxacin
nebulized levofloxacin</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Bilateral Endoscopy Findings Using POSE Scores</title>
          <description>The Perioperative Sinus Endoscopy (POSE) instrument is a specific tool to endoscopically assess the sinus cavities of patients who have undergone endoscopic sinus surgery.
Each POSE score has a minimum of 0 and a maximum of 16, with a higher score indicating a worse outcome.
Here, the Left and Right POSE scores are summed and the difference between baseline and the 14 day after treatment is reported.
The change in bilateral POSE score can in principle be -32 to +32, with increased scores indicating worse outcome and negative scores indicating improvement over the treatment period.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.889" spread="5.442"/>
                    <measurement group_id="O2" value="-4.545" spread="2.806"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Assuming that the non-inferiority limit of topical therapy is 20% of that for oral therapy.</non_inferiority_desc>
            <p_value>0.390</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-treatment Culture Negativity</title>
        <description>Post-treatment culture negativity, defined as less than 1+ growth of organisms. A subject is counted '1' if both nares are free of bacterial growth, and '0' if growth is 1+ of more</description>
        <time_frame>14 days after treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral Placebo With Nebulized Intranasal Levofloxacin</title>
            <description>Placebo oral tablet by mouth daily for 14 consecutive days along with nebulized levofloxacin 125 mg twice daily for 14 consecutive days
oral levofloxacin
nebulized levofloxacin</description>
          </group>
          <group group_id="O2">
            <title>Oral Antibiotics With Nebulized Intranasal Placebo</title>
            <description>Levofloxacin 500 mg by mouth once daily for 14 consecutive days, along with intranasal placebo solution twice daily for 14 consecutive days.
oral levofloxacin
nebulized levofloxacin</description>
          </group>
        </group_list>
        <measure>
          <title>Post-treatment Culture Negativity</title>
          <description>Post-treatment culture negativity, defined as less than 1+ growth of organisms. A subject is counted '1' if both nares are free of bacterial growth, and '0' if growth is 1+ of more</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Assuming that the non-inferiority limit of topical therapy is 20% of that for oral therapy.</non_inferiority_desc>
            <p_value>0.036</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in the Total Bacterial Community Following Treatment as Determined by DNA Sequencing.</title>
        <description>The bacterial community was determined using a 16S rRNA quantitative PCR processed using Quantitative Insights into Microbial Ecology (QIIME) software, version 1.8 to yield the operational taxonomic units in each subject sample. The scale is bounded at zero with an increasing score indicating a larger number of distinct bacterial species.</description>
        <time_frame>14 days after treatment</time_frame>
        <population>Data was only collected on the first consecutive 8 randomized participants and had equal numbers in each group</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Placebo With Nebulized Intranasal Levofloxacin</title>
            <description>Placebo oral tablet by mouth daily for 14 consecutive days along with nebulized levofloxacin 125 mg twice daily for 14 consecutive days
oral levofloxacin
nebulized levofloxacin</description>
          </group>
          <group group_id="O2">
            <title>Oral Antibiotics With Nebulized Intranasal Placebo</title>
            <description>Levofloxacin 500 mg by mouth once daily for 14 consecutive days, along with intranasal placebo solution twice daily for 14 consecutive days.
oral levofloxacin
nebulized levofloxacin</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Total Bacterial Community Following Treatment as Determined by DNA Sequencing.</title>
          <description>The bacterial community was determined using a 16S rRNA quantitative PCR processed using Quantitative Insights into Microbial Ecology (QIIME) software, version 1.8 to yield the operational taxonomic units in each subject sample. The scale is bounded at zero with an increasing score indicating a larger number of distinct bacterial species.</description>
          <population>Data was only collected on the first consecutive 8 randomized participants and had equal numbers in each group</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.40" spread="9.530"/>
                    <measurement group_id="O2" value="6.700" spread="7.404"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Oral Placebo With Nebulized Intranasal Levofloxacin</title>
          <description>Placebo oral tablet by mouth daily for 14 consecutive days along with nebulized levofloxacin 125 mg twice daily for 14 consecutive days
oral levofloxacin
nebulized levofloxacin</description>
        </group>
        <group group_id="E2">
          <title>Oral Antibiotics With Nebulized Intranasal Placebo</title>
          <description>Levofloxacin 500 mg by mouth once daily for 14 consecutive days, along with intranasal placebo solution twice daily for 14 consecutive days.
oral levofloxacin
nebulized levofloxacin</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Research Program Manager</name_or_title>
      <organization>UR Medicine Otolaryngology</organization>
      <phone>5852751186</phone>
      <email>paul_allen@urmc.rochester.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

